CAMP4 Therapeutics Corporation (CAMP)
NASDAQ: CAMPHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CAMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $240.97M
- EPS (TTM)
- -$2.32
- Dividend yield
- None
- 52-week range
- 2.86 – 7.75
- Day range
- 3.84 – 4.09
- Volume / Avg
- 148.50K / 279.95K
- Beta
- —
- Shares outstanding
- 62.75M
- Next earnings
- Nov 5, 2026
52-week range
CAMP stock today
On Oct 7, CAMP ended the session at $3.84, shedding $0.12 (3.03%), versus the S&P 500's 0.22% decline. Shares are 50.5% below their 52-week high of $7.75, set on Mar 9, 2026 and 34.3% above the 52-week low of $2.86, in the middle of the past year's range. CAMP is down 37.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 16.7%.
CAMP4 Therapeutics has posted a net loss over the last twelve months (EPS of -$2.32), so its P/E ratio is not meaningful. CAMP4 Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About CAMP4 Therapeutics
Company profileCamp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joshua Mandel-Brehm
- Headquarters
- Cambridge, MA
- Employees
- 48
- IPO year
- 2024
- Website
- camp4tx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$10.57+175.26%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.19
CAMP4 Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PYXSPyxis Oncology Inc. | 2.01 | -0.49% | $240.11M | vs CAMP |
| VOGXVogenx Inc | 16.16 | -1.40% | $240.06M | vs CAMP |
| LCTXLineage Cell Therapeutics Inc. | 0.9476 | +1.03% | $239.66M | vs CAMP |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs CAMP |
| QTTBQ32 Bio Inc. | 7.99 | -1.48% | $237.86M | vs CAMP |
| SLGLSol-Gel Technologies Ltd. | 71.95 | -4.88% | $235.55M | vs CAMP |
| NAUTNautilus Biotechnology Inc. | 1.96 | +10.73% | $249.42M | vs CAMP |
| IMRXImmuneering Corporation Class A | 3.86 | +0.78% | $249.73M | vs CAMP |
Indexes, lists and sector
Appears in lists
CAMP4 Therapeutics stock FAQ
What is CAMP4 Therapeutics's stock price today?
CAMP last traded at $3.84 as of Oct 7, 4:00 PM EDT, down 3.03% on the day. Prices are delayed at least 15 minutes.
When is CAMP4 Therapeutics's next earnings date?
CAMP4 Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.19.
Who is CAMP4 Therapeutics's CEO?
Mr. Joshua Mandel-Brehm is the chief executive officer of CAMP4 Therapeutics Corporation, which has about 48 employees.
What is the CAMP 52-week high?
The 52-week high for CAMP is $7.75 and the 52-week low is $2.86. The stock is currently 50.5% below its high.